The orexin agonist, FDA approved in August, is being studied for ADHD and Parkinson's fatigue. Takeda's R&D head compares its reach to GLP-1 drugs, though data is early.
Recap by typeshit. Full story at DongA Science.
She describes MOTS-c as a messenger made by mitochondria that may help muscles handle sugar. The framing is hers and not an established health claim.
Medscape covers research tying GLP-1 drug use to lower alcohol consumption. Tap through for the study details and what researchers found.
In a small 2022 trial, whey beat leucine-boosted collagen for muscle growth, while evidence that collagen prevents sports injuries is still missing.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Refused by a doctor for not being overweight, she got doses from an acquaintance and spent two days ill. She writes about why she wanted to be thinner anyway.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Loading…